Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ranibizumab, ATC S01LA04 für die Zeit 01.09.2026 - 31.08.2028

Section 130a, paragraph 8, of the German Social Code, Book V (SGB V), enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Act Against Restraints of Competition (GWB). For the pharmaceuticals to be specified by the bidder in Annex 2 to the contract, for the aforementioned substance Ranibizumab, ATC S01LA04, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until new pharmaceutical discount contracts come into force. A discount contract under the approval model for the aforementioned substance comes into force for the first time on 01.09.2026 and expires on 31.08.2028. It automatically expires with the entry into force of the exclusive contract, regardless.